Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Genentech Inc | 3,458 |
| 2 | F Hoffmann La Roche AG | 1,521 |
| 3 | University of Texas System | 738 |
| 4 | Institut National de la Sante et de la Recherche Medicale INSERM | 411 |
| 5 | University of Texas at Austin | 335 |
| 6 | Gilead Sciences Inc | 303 |
| 7 | Merck Sharp and Dohme LLC | 253 |
| 8 | MedImmune Ltd | 239 |
| 9 | Toray Industries Inc | 224 |
| 10 | Mereo Biopharma 5 Inc | 202 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 19,611 |
| 2 | A61K | Medicinal preparations | 19,236 |
| 3 | C07K | Peptides | 12,993 |
| 4 | C07D | Heterocyclic compounds | 5,124 |
| 5 | C12N | Microorganisms, enzymes | 4,373 |
| 6 | G01N | Investigating / analysing materials | 3,815 |
| 7 | C12Q | Measuring/testing involving enzymes | 1,865 |
| 8 | Y02A | Climate change adaptation | 1,864 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 784 |
| 10 | C07F | Organometallic compounds | 650 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Biochemical and Molecular Research | 2 |
| 2 | Amino Acid Enzymes and Metabolism | 1 |
| 3 | Cancer, Hypoxia, and Metabolism | 1 |
| 4 | Clinical Nutrition and Gastroenterology | 1 |
| 5 | Colorectal Cancer Treatments and Studies | 1 |
| 6 | Corneal Surgery and Treatments | 1 |
| 7 | Enzyme function and inhibition | 1 |
| 8 | Nitric Oxide and Endothelin Effects | 1 |
| 9 | Photosynthetic Processes and Mechanisms | 1 |
| 10 | Proteoglycans and glycosaminoglycans research | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Barbara S. Slusher | Johns Hopkins University | 17 |
| 2 | David A. Cooney | National Institutes of Health | 6 |
| 3 | D. M. Kochhar | University of Virginia | 5 |
| 4 | Eva Prchalová | Johns Hopkins University | 5 |
| 5 | H Zalkin | Purdue University West Lafayette | 5 |
| 6 | Jesse Alt | Johns Hopkins University | 5 |
| 7 | Bengt Långström | Uppsala University Hospital | 4 |
| 8 | Camilo Rojas | Johns Hopkins University | 4 |
| 9 | Joseph Roberts | University of South Carolina | 4 |
| 10 | Ajit G. Thomas | Johns Hopkins University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation | 2013 | 594 | Protein Kinase Regulation and GTPase Signaling |
| Functional significance of cumulus expansion in the mouse: Roles for the preovulatory synthesis of hyaluronic acid within the cumulus mass | 1993 | 288 | Sperm and Testicular Function |
| Glutamine and Cancer | 1993 | 288 | Cancer, Hypoxia, and Metabolism |
| Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. | 1982 | 279 | Cancer Cells and Metastasis |
| We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine | 2018 | 247 | Cancer-related Molecular Pathways |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of H-L-Don-OH?
Which organizations hold the most patents related to this compound?
What research topics are most commonly associated with this compound in the scientific literature?
Who are the most prolific authors publishing on this compound?
What is the recent patent activity trend for this compound?